Manages exogenous obesity. ANDA 200272, held by Elite Labs. Phentermine Hydrochloride.
As of Nov 16, 2026, ANDA 200272 (Phentermine Hydrochloride), held by Elite Labs, was first approved by FDA on Jan 31, 2011, with 2 approved supplements and 0 published complete response letters.
Phentermine hydrochloride Tablets are indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index ≥ 30 kg/m 2, or ≥ 27 kg/m 2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia). Below is a chart of body mass index (BMI) based on various heights and weights. BMI is calculated by taking the patient's weight, in kilograms (kg), divided by the patient's height, in meters (m), squared. Metric conversions are as follows: pounds ÷ 2.2 = kg; inches × 0.0254 = meters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 31, 2011 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Phentermine Hydrochloride37.5MG · tablet;oral | Phentermine Hydrochloride | Rx |
| May 31, 2017 | Supplement 6Labeling · Standard review | Approved | None posted |
| Dec 5, 2012 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jan 31, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters